21 / 23
* Response criteria met again in repeat assessment performed ≥5 weeks after initial documentation of CR or PR.
†
Died prior to tumor assessment.
First Line Avelumab ( Part B)
Preliminary Efficcacy results
D´Angelo et al. ASCO 2017